Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation

Transplantation

Volumn 74, Issue 1, 2002, Pages 49-54

  Lin, Thomas S ^a   Zahrieh, David ^a   Weller, Edie ^a   Alyea, Edwin P ^a   Antin, Joseph H ^a   Soiffer, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD6 ANTIGEN; VIRUS ANTIGEN;

ACUTE DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DOCUMENTATION; DONOR; EXPOSURE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTECTION; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS REACTIVATION;

EID: 0037099415     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200207150-00009     Document Type: Article

References (31)

1. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
2. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis
3. Risk factors for cytomegalovirus infection after human marrow transplantation
4. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
5. A randomized, controlled trial of prophylactic ganciclovir for cytomegalo-virus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group
6. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies
7. The transplanted kidney as a source of cytomegalovirus infection
8. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies
9. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation: A multicenter evaluation
10. Cytomegalovirus infections in heart and heart and lung transplant recipients
11. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: Rationale and results
12. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
13. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters
14. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
15. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients
16. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro
17. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
18. Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients
19. CD8-depleted donor leukocyte transfusions for cytomegalovirus antigenemia in patient with acute lymphoblastic leukemia treated with allogeneic CD34(+) cell transplantation
20. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections
21. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
22. T cell depletion of human bone marrow: Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads
23. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors
24. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts
25. In vitro comparison of two methods of T cell depletion associated with different rates of graft failure after allogeneic marrow transplantation
26. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection
27. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
28. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
29. Differences between the quantitative antigenemia assay and COBAS Amplicor Monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients
30. Comparison of the Murex Hybrid Capture CMV DNA (v2.0) assay and the pp65 CMV antigenemia test for the detection and quantitation of CMV in blood samples from immunocompromised patients
31. Valganciclovir